Physician profile
Vincent J Carsillo, II
NPI 1467444208
$191,316.75
in general payments reported to CMS, 2019-2025
16 companies · $111K in 2025
The $111K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $16.63 · 2021: $459 · 2022: $181 · 2023: $852 · 2024: $79K · 2025: $111K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $161K · Travel and Lodging: $23K · Food and Beverage: $3,333 · Consulting Fee: $3,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $161,090.00 |
| Travel and Lodging | $23,106.96 |
| Food and Beverage | $3,333.11 |
| Consulting Fee | $3,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $72,133.97 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Lilly USA, LLC | $70,996.66 | 2024-2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46,689.21 | 2023-2025 | Jardiance |
| Horizon Therapeutics Plc | $416.47 | 2019-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $278.37 | 2023-2025 | Acthar, Terlivaz |
| Calliditas Therapeutics US INC. | $208.30 | 2022-2024 | |
| Akebia Therapeutics INC | $146.56 | 2019-2025 | Vafseo |
| Tosoh Bioscience, INC. | $118.24 | 2021 | |
| Aurinia Pharma U.S., INC. | $108.80 | 2021 | |
| Glaxosmithkline, LLC. | $65.99 | 2023-2025 | Jesduvroq, Benlysta |
| Astrazeneca Pharmaceuticals Lp | $62.49 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $25.01 | 2022 | |
| Amgen INC. | $20.30 | 2021 | |
| Vifor Pharma, INC. | $16.58 | 2022 | |
| Fresenius USA Marketing, INC. | $16.40 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $13.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Carsillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.